CAR T antigen selection

1
CAR T Therapy
www.creative-biolabs.com/car-t
2
CAR T antigen selection
In a narrow sense of cancer biomarker, it is
limited to proteins the most used to challenge in
the clinical applications, especially in the
CAR-T therapy.
It is usually identifiable or measurable in the
blood, urine or other convenient body fluids by
PCR, ELISA, and other conventional immune assays.
In this sense, biomarkers can be categorized into
genetic, epigenetic, proteomic, glycomic, and
imaging biomarkers for cancer diagnosis,
prognosis, and epidemiology.
1
of
4
3
As the most basic foundation of therapeutic
effect, these cancer biomarkers commonly possess
the following characteristics
1
2
3
Involve in the canceration process, correlate
with the disease changes, like deterioration and
improvement
Manifest as a relatively high expression or even
unique expression on the surface of cancerous and
precancerous tissue than other normal cells to be
measured and distinguished easily and reliably
for an acceptable safety, especially the mutant
proteins, which is the most specific biomarkers
for the only origination from an existing tumor
Relatively stable in response to other unrelated
factors.
2
of
4
4
www.bigidea.com
car t cell evaluation
With advanced technologies and experienced
researchers, scientists from Creative Biolabs can
design and operate a full range of validation
assay services according to your T cells
engineered objective. In detail, the following
assays are adopted for this purpose
Cytokine Release Test
CAR Expression Test
The widely used methods include enzyme-linked
immuno spot assay (ELISpot), intracellular
cytokine staining assay (ICS), and flow cytometry.
The methods include western blot (WB),
enzyme-linked immunosorbent assay (ELISA), flow
cytometry (FCM), immune-histochemical (IHC), etc.
In Vitro Cytotoxicity Test
CAR Cell Proliferation Test
CAR-T cells undergo antigen-independent
proliferation that could increase cell-mediated
toxicity and raise the concern of immortalization
of infused CAR-T cells
Our scientists have developed the second and the
third generation CAR products, which can enhance
the persistence of CAR-T cells or -NK cells
proliferation.
Efficacy Test
Viability and Bio-distribution Analysis
Creative Biolabs is able to provide therapeutic
efficacy test service for a proof-of-concept or
therapeutic efficacy validation, by utilizing
appropriate animal models
All tests are conducted by experienced
technicians on the most appropriate models with
the most advanced techniques
3
of
4
5
CAR T pubulication
In a broad sense, cancer biomarker is an
indicative of the presence of cancer in the body
or a molecule secreted by a tumor or a specific
response of the body to the presence of cancer.
Contact Us www.creative-biolabs.com/car-tom
of
4
4
6
THANK YOU